Leerink Swann resumes coverage on Biogen IDEC (Nasdaq: BIIB) with an Outperform rating. $55/share valuation.

Leerink analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE